Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 plus carboplatin and pemetrexed as first-line therapy for metastatic non-squamous non-small cell lung cancer
CTR20182009Phase 3Terminated
- Sponsor
- Akeso, Inc.
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab in non-squamous non-small cell lung cancer, sponsored by Akeso, Inc.. Started Nov 2018; status: terminated.
02
Drugs
penpulimab
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on CTR20182009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182009.